The chronic myelogenous leukemia treatment market is expected to experience significant growth through 2032, driven by increasing disease prevalence and multiple recent FDA approvals.
The FDA issued 16 oncology approvals between July and September 2024, addressing the global surge in cancer cases, particularly among individuals under 50.
Enliven Therapeutics announced updated Phase 1 data for ELVN-001, presented at the ESH-iCMLf conference, showing clinical benefit in heavily pretreated CML patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.